In vitro comparison of the effect of inhalation delay and flow rate on the emitted dose from three valved holding chambers

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue SUPPL. 1, 2014, Pages

  Slator, Lois ^a   Von Hollen, Dirk ^a   Sandell, Dennis ^b   Hatley, Ross H M ^a  

^a PHILIPS RESEARCH LABORATORIES   (Germany)

^b S5 Consulting   (Sweden)

Author keywords

emitted dose; flow rate; in vitro equivalence; inhalation delay; pMDI; valved holding chamber

Indexed keywords

SALBUTAMOL; SALBUTAMOL SULFATE; AEROSOL;

AEROSOL; ARTICLE; AUTOMATION; DRUG DELIVERY DEVICE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INHALATION; INHALATION DELAY; MEDICAL DEVICE; METERED DOSE INHALER; VALVED HOLDING CHAMBER; CHEMISTRY; COMPARATIVE STUDY; DEVICES; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; FLOW KINETICS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PARTICLE SIZE; PRESSURE; TIME;

ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; INHALATION; METERED DOSE INHALERS; PARTICLE SIZE; PRESSURE; RHEOLOGY; TIME FACTORS;

EID: 84904788402     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1061     Document Type: Article

References (17)

1. Lavorini F, and Fontana GA: Targeting drugs to the airways: The role of spacer Devices. Expert Opin Drug Deliv. 2009;6:91-102.
2. Newman SP, Millar AB, Lennard-Jones TR, Morén F, and Clarke SW: Improvement of pressurised aerosol Deposition with Nebuhaler spacer Device. Thorax. 1984;39:935-941. (Pubitemid 15211833)
3. Corr D, Dolovich M, McCormack D, Ruffin R, Obminski G, and Newhouse M: Design and characteristics of a portable breath-actuated particle size selective medical aerosol inhaler. J Aerosol Sci. 1982;13:1-7. (Pubitemid 12538643)
4. Rau JL: Practical problems with aerosol therapy in COPD. Respir Care. 2006;51:158-172. (Pubitemid 46888414)
5. Barry PW, Robertson CF, and O'Callaghan C: Optimum use of a spacer Device. Arch Dis Child. 1993;69:693-694. (Pubitemid 24009918)
6. Newman SP, Woodman G, Morén F, and Clarke SW: Bronchodilator therapy with Nebuhaler: how important is the Delay between firing the dose and inhaling? Br J Dis Chest. 1988;82:262-267.
7. Agnew JE: Physical properties and mechanisms of Deposition of aerosols. In: SW Clarke, and D Pavia, (eds). Aerosols and the Lung: Clinical and Experimental Aspects. Butterworths, London; pp. 49-70, 1984.
8. Dolovich MA, MacIntyre NR, AnDerson PJ, Camargo CA Jr, Chew N, Cole CH, Dhand R, Fink JB, Gross NJ, Hess DR, Hickey AJ, Kim CS, Martonen TB, Pierson DJ, Rubin BK, and Smaldone GC: Consensus statement: aerosols and Delivery Devices. American Association for Respiratory Care. Respir Care. 2000;45:589-596; Erratum in Respir Care. 2000;45:1416. (Pubitemid 30484799)
9. Barry PW, and O'Callaghan C: Poor output of salbutamol from a spacer Device: effect of spacer static charge and multiple actuations. Thorax. 1994;49:402P.
10. O'Callaghan C, Lynch J, Cant M, and Robertson C: Improvement in sodium cromoglycate Delivery from a spacer Device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax. 1993;48: 603-606. (Pubitemid 23188432)
11. Berg E, Madsen J, and Bisgaard H: In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Respir J. 1998;12: 472-476. (Pubitemid 28389548)
12. Newman SP, Pavia D, Garland N, and Clarke SW: Effects of various inhalation moDes on the Deposition of radioactive pressurized aerosols. Eur J Respir Dis. 1982;63(Suppl 119):57-65. (Pubitemid 12060356)
13. Heslop K: How to use pressurised metered dose inhalers. Nurs Times. 2008;104(47):78-80.
14. Pool JB, Greenough A, Gleeson JGA, and Price JF: Inhaled bronchodilator treatment via the Nebuhaler in young asthmatic patients. Arch Dis Child. 1988;63:288-291. (Pubitemid 18094667)
15. Schultz A, Le Souëf T, Venter A, Zhang G, Devadason SG, and Le Souëf PN: Aerosol inhalation from spacers and valved holding chambers requires few tidal breaths for children. Pediatrics. 2010;126:e1493-e1498.
16. Hatley RHM, Von Hollen D, SanDell D, and Slator L: In vitro characterization of the OptiChamber Diamond valved holding chamber. J Aerosol Med Pulm Drug Deliv. 2014; 27:S-24-S-36.
17. European Medicines Agency/Committee for Medicinal Products for Human Use (CHMP): GuiDeline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for Demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. European Medicines Agency, London, 22 January 2009. Doc. Ref. CPMP/EWP/4151/00 Rev.